Vitrolife Signs Collaboration Agreement with Cellartis

STOCKHOLM--(Business Wire)--
Regulatory News:

Vitrolife (STO:VITR) has entered into a new 3-year collaboration agreement with
Cellartis AB regarding the development of new products for the culture, handling
and differentiation of stem cells. The agreement extends the previous
collaboration between the companies.

"The stem cell field is experiencing strong growth, not least since President
Obama lifted the ban on research into certain stem cell lines," says Tony
Winslöf, Head of Business Development at Vitrolife. The collaboration with
Cellartis comes at the right time to develop the stem cell products of tomorrow,
meeting the scientific, regulatory and commercial demands of the future.

"Cellartis is a world-leading company with regard to competence above all in the
field of pluripotent stem cells, and as such is a valuable resource in
developing the right products for a rapidly growing market," says Magnus
Nilsson, Vitrolife`s CEO, who also points out that "stem cell culture is
difficult and both Vitrolife and Cellartis have long experience of optimizing
culture environments for sensitive cells."

The financial scope of the agreement will not be made public.

Gothenburg
October 8, 2009

Magnus Nilsson
CEO

Vitrolife is a global biotechnology/medical device Group that works with
developing, manufacturing and selling advanced products and systems for the
preparation, cultivation and storage of human cells, tissue and organs. The
company has business activities within three product areas: Fertility,
Transplantation and Stem Cell Cultivation.

The Fertility product area works with nutrient solutions (media),
cryopreservation products and advanced consumable instruments such as needles
and pipettes, for the treatment of human infertility. The Transplantation
product area works with solutions and systems to evaluate and maintain organs
outside the body order to select usable organs and keeping them in optimal
condition while waiting for transplantation. The Stem Cell Cultivation product
area works with media and instruments to enable the use and handling of stem
cells for therapeutic purposes.

Vitrolife today has approximately 150 employees and the company`s products are
sold in more than 80 markets. The company is headquartered in Gothenburg,
Sweden, and there are subsidiaries in USA, Australia, France, Italy and Japan.
Production facilities are housed in Sweden and USA.

The Vitrolife share is listed on NASDAQ OMX Stockholm, Small Cap.

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity
number 556354-3452.
Tel: +46 31 721 80 00. Fax: +46 31 721 80 99. E-mail: info@vitrolife.com.
Homepage: www.vitrolife.com.

This is a translation of the Swedish version of the press release. When in
doubt, the Swedish wording prevails.

This information was brought to you by Cision http://www.cisionwire.com

Vitrolife
Magnus Nilsson, CEO
phone +46 31 721 80 61
or
Eva Nilsagård, CFO
phone +46 31 721 80 13

Copyright Business Wire 2009